The classification of hospitalized XXXX with @entity4854 and its implication on outcome: results from a prospective observational study in Internal Medicine.

@entity1 @entity4051 @entity6 @entity392 @entity2412 @entity4854 @entity1602 @entity413
UNASSIGNED: The relevance of classifying @entity1602 @entity392 ( @entity392 ) as known @entity6 ( @entity6 ), @entity6 ( @entity6 ), and @entity4854 ( @entity4854 ) is unclear. The aim of this study was to determine the prevalence, in-hospital mortality, and length of stay (LOS) of three different phenotypes of @entity392 . Fasting @entity413 >= 126  mg/dL (7  mmol/L) or random blood @entity413 >= 200  mg/dL (11.1  mmol/L) defined @entity392 who were categorized into three groups: @entity6 ; @entity6 (no history of @entity6 and HbA1c >= 48  mmol/mol); @entity4854 (no history of @entity6 and HbA1c <48  mmol/mol). The end points of the study were in-hospital mortality and LOS. Of 1447 consecutive enrolled subjects, the prevalence of @entity392 was 28.6  % (415/1447), of these 71.6  % had @entity6 , 21.2  % @entity4854 , and 7.2  % @entity6 , respectively. In-hospital death was 3.9  % in normoglycemic and 6.0  % in @entity1602 subjects. Individuals with @entity4854 had an increased risk of in-hospital death (7.9  %) (HR 2.17, 95  % CI 1.18-4.9; p  =  0.039), while this was not observed for @entity6 and @entity6 @entity1 . The mean LOS was greater in @entity6 and @entity4854 subjects. @entity4854 is common, and is associated with an increased risk of in-hospital mortality and extension of hospital stay. @entity4051 c along with clinical history is a useful tool to identify subgroups of @entity1602 @entity392 . Individuals with @entity4854 have a longer LOS, and a double risk of in-hospital mortality. Additionally, identifying previously unknown @entity6 represents a remarkable opportunity for prevention of @entity2412 .
